Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study

自身抗体 儿科 血清学 内科学
作者
Núria Gresa-Arribas,Maarten J. Titulaer,Abiguei Torrents,Esther Aguilar,Lindsey McCracken,Frank Leypoldt,Amy J. Gleichman,Rita J. Balice-Gordon,Myrna R. Rosenfeld,David R. Lynch,Francesc Graus,Josep Dalmau
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:13 (2): 167-177 被引量:704
标识
DOI:10.1016/s1474-4422(13)70282-5
摘要

Anti-N-methyl-d-aspartate (NMDA) receptor encephalitis is a severe but treatable autoimmune disorder which diagnosis depends on sensitive and specific antibody testing. We aimed to assess the sensitivity and specificity of serum and CSF antibody testing in patients with anti-NMDA receptor encephalitis, and the relation between titres, relapses, outcome, and epitope repertoire.In this observational study, we used rat brain immunohistochemistry and cell-based assays (CBA) with fixed or live NMDA receptor-expressing cells to determine the sensitivity and specificity of antibody testing in paired serum and CSF samples. Samples were obtained at diagnosis from patients with anti-NMDA receptor encephalitis and from control participants worldwide. We deemed a patient to be antibody positive if their serum, their CSF, or both tested positive with both immunohistochemistry and CBA techniques; we determined titres with serial sample dilution using brain immunohistochemistry. We examined samples from 45 patients (25 with good outcome [modified Rankin Scale, mRS 0-2], ten with poor outcome [mRS 3-6], and ten with relapses) at three or more timepoints. We determined the epitope repertoire in the samples of 23 patients with CBA expressing GluN1-NMDA receptor mutants.We analysed samples from 250 patients with anti-NMDA receptor encephalitis and 100 control participants. All 250 patients had NMDA receptor antibodies in CSF but only 214 had antibodies in serum (sensitivity 100.0% [98.5-1000%] vs 85.6% [80.7-89.4%], p<0.0001). Serum immunohistochemistry testing was more often in agreement with CBA with fixed cells (77 [71%] of 108) than with CBA with live cells (63 [58%] of 108, p=0.0056). In multivariable analysis, CSF and serum titres were higher in patients with poor outcome than in those with good outcome (CSF dilution 340 vs 129, difference 211, [95% CI 1-421], p=0.049; serum dilution 7370 vs 1243, difference 6127 [2369-9885], p=0.0025), and in patients with teratoma than in those without teratoma (CSF 395 vs 110, difference 285 [134-437], p=0.0079; serum 5515 vs 1644, difference 3870 [548-7193], p=0.024). Over time there was a decrease of antibody titres in the 35 patients with good or poor outcome and samples followed at three timepoints regardless of outcome (from diagnosis to last follow-up: CSF 614 to 76, difference 538 [288-788]; serum 5460 to 1564, difference 3896 [2428-5362]; both p<0.0001). Relapses were associated with a change in titre more often in CSF than in serum (14 of 19 vs seven of 16, p=0.037). After recovery, 24 of 28 CSF samples and 17 of 23 serum samples from patients remained antibody positive. Patients' antibodies targeted a main epitope region at GluN1 aminoacid 369; the epitope repertoire did not differ between patients with different outcomes, and did not change during relapses.The sensitivity of NMDA receptor antibody testing is higher in CSF than in serum. Antibody titres in CSF and serum were higher in patients with poor outcome or teratoma than in patients with good outcome or no tumour. The titre change in CSF was more closely related with relapses than was that in serum. These findings emphasise the importance of including CSF in antibody studies, and that antibody titres can complement clinical assessments.Dutch Cancer Society, National Institutes of Health, McKnight Neuroscience of Brain Disorders award, the Fondo de Investigaciones Sanitarias, ErasmusMC fellowship, and Fundació la Marató de TV3.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
12秒前
秋半梦完成签到,获得积分10
14秒前
李爱国应助科研通管家采纳,获得10
17秒前
科研通AI2S应助科研通管家采纳,获得10
17秒前
搜集达人应助科研通管家采纳,获得10
17秒前
打地鼠工人完成签到,获得积分10
18秒前
彩色半烟完成签到,获得积分10
20秒前
量子星尘发布了新的文献求助10
24秒前
Ning完成签到,获得积分10
27秒前
图图完成签到,获得积分10
27秒前
勤奋的灯完成签到 ,获得积分10
27秒前
ludong_0完成签到,获得积分10
27秒前
Asumita完成签到,获得积分10
28秒前
双青豆完成签到 ,获得积分10
28秒前
30秒前
fxy完成签到 ,获得积分10
31秒前
合适的幻然完成签到,获得积分10
31秒前
沐雨汐完成签到,获得积分10
33秒前
35秒前
36秒前
jiayoujijin完成签到 ,获得积分10
36秒前
淡然思卉完成签到,获得积分10
37秒前
争当科研巨匠完成签到,获得积分10
37秒前
英姑应助认真的刺猬采纳,获得10
44秒前
好大一只小坏蛋完成签到,获得积分20
44秒前
站走跑完成签到 ,获得积分10
47秒前
步步高完成签到,获得积分10
49秒前
无私的雪瑶完成签到 ,获得积分10
49秒前
小杨完成签到,获得积分20
50秒前
小花完成签到 ,获得积分10
55秒前
宁夕完成签到 ,获得积分10
59秒前
西宁完成签到,获得积分10
59秒前
拼搏的羊青完成签到 ,获得积分10
1分钟前
科目三应助asd113采纳,获得10
1分钟前
deng203完成签到 ,获得积分20
1分钟前
1分钟前
时米米米完成签到,获得积分10
1分钟前
浅浅完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
帅气的藏鸟完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022